Optimizing the dosing schedule of TNP-470 [O-(chloroacetyl-carbamoyl) fumagillol] enhances its antitumor and antiangiogenic efficacies

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 2, 2003, Pages 669-674

  Koyanagi, Satoru ^a   Nakagawa, Hiroo ^b   Kuramoto, Yukako ^a   Ohdo, Shigehiro ^b   Soeda, Shinji ^a   Shimeno, Hiroshi ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; FUMAGILLOL CHLOROACETYLCARBAMATE; METHIONYL AMINOPEPTIDASE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CIRCADIAN RHYTHM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; ENZYME ACTIVITY; FLUID INTAKE; FOOD INTAKE; LIGHT DARK CYCLE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; TOXICITY TESTING;

AMINOPEPTIDASES; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; CHRONOTHERAPY; CYCLOHEXANES; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED ICR; SARCOMA, EXPERIMENTAL; SESQUITERPENES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037309359     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.043562     Document Type: Article

References (30)

1. Asano M, Yukita A, Matsumoto T, Kondo S, and Suzuki H (1995) Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor 121. Cancer Res 55:5296-5301.
2. Beal SL and Sheiner LB, editors (1992) NONMEM User's Guides, NONMEM Project Group. University of California at San Francisco, San Francisco.
3. Boehm T, Folkman J, Browder T, and O'Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond) 390:404-407.
4. Cal JC, Dorian C, and Cambar J (1986) Circadian and circannual changes in nephrotoxic effects of heavy metals and antibiotics. Annu Rev Chronopharmacol 2:143-176.
5. Cretton-Scott E, Placidi L, McClure H, Anderson DC, and Sommadossi JP (1996) Pharmacokinetics and metabolism of O-(chloroacetyl-carbamoyl) fumagillol (TNP-470, AGM-1470) in rhesus monkeys. Cancer Chemother Pharmacol 38:117-122.
6. Damiola F, Le Minh N, Preitner N, Kornmann B, Fleury-Olela F, and Schibler U (2000) Restricted feeding uncouples circadian oscillators in peripheral tissues from the central pacemaker in the suprachiasmatic nucleus. Genes Dev 14:2950-2961.
7. Dong Z, Greene G, Pettaway C, Dinney CP, Eue I, Lu W, Bucana CD, Balbay MD, Bielenberg D, and Fidler IJ (1999) Suppression of angiogenesis, tumorigenicity and metastasis by human prostate cancer cells engineered to produce interferon-beta. Cancer Res 59:872-879.
8. Figg WD, Pluda JM, Lush RM, Saville MW, Wyvill K, Reed E, and Yarchoan R (1997) The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. Pharmacotherapy 17:91-97.
9. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186.
10. Griffith EC, Su Z, Turk BE, Chen S, Chang YH, Wu Z, Biemann K, and Liu JO (1997) Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem Biol 4:461-471.
11. Halberg F and Halberg G (1984) Chronopharmacology and further steps toward chronotherapy. In Pharmacokinetic Basis for Drug Treatment (Benet LZ, Massoud N, and Gambertoglio JG eds) pp 221-248, Raven Press, New York.
12. Holcslaw TL, Miya TS, and Bousquet WS (1975) Circadian rhythms in drug action and drug metabolism in the mouse. J Pharmacol Exp Ther 195:320-332.
13. Hori A, Ikeyama S, and Sudo K (1994) Suppression of cyclin D1 mRNA expression by the angiogenesis inhibitor TNP-470 (AGM-1470) in vascular endothelial cells. Biochem Biophys Res Commun 204:1067-1073.
14. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, and Folkman J (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature (Lond) 348:555-557.
15. Katzenstein HM, Rademaker AW, Senger C, Salwen HR, Nguyen NN, Thorner PS, Litsas L, and Cohn SL (1999) Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth ofhuman neuroblastoma in nude mice inversely correlates with tumor burden. Clin Cancer Res 5:4273-4278.
16. Koren S, Whorton EB Jr, and Fleischmann WR Jr (1993) Circadian dependence of interferon antitumor activity in mice. J Natl Cancer Inst 85:1927-1932.
17. Koyanagi S, Ohdo S, Yukawa E, and Higuchi S (1997) Chronopharmacological study of interferon-α in mice. J Pharmacol Exp Ther 283:259-264.
18. Kusaka M, Sudo K, Matsutani E, Kozai Y, Marui S, Fujita T, Ingber D, and Folkman J (1994) Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 69:212-216.
19. Logothetis CJ, Wu KK, Finn LD, Daliani D, Figg W, Ghaddar H, and Gutterman JU (2001) Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 7:1198-1203.
20. Lowther WT, McMillen DA, Orville AM, and Matthews BW (1998) The antiangiogenic agent fumagillin covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidase. Proc Natl Acad Sci USA 95:12153-12157.
21. Ohdo S, Koyanagi S, Suyama H, Higuchi S, and Aramaki H (2001) Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. Nature Med 7:356-360.
22. O'Reilly MS, Brem H, and Folkman J (1995) Treatment of murine hemangioendotheliomas with the angiogenesis inhibitor AGM-1470. J Pediatr Surg 30:325-330.
23. Placidi L, Cretton-Scott E, de Sousa G, Rahmani R, Placidi M, and Sommadossi JP (1995) Disposition and metabolism of the angiogenic moderator O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) in human hepatocytes and tissue microsomes. Cancer Res 55:3036-3042.
24. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, and Crews CM (1997) The antiangiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA 94:6099-6103.
25. Slaton JW, Perrotte P, Inoue K, Dinney CP, and Fidler IJ (1999) Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5:2726-2734.
26. Shusterman S, Grupp SA, Barr R, Carpentieri D, Zhao H, and Maris JM (2001) The angiogenesis inhibitor TNP-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin Cancer Res 7:977-984.
27. Takane H, Ohdo S, Yamada T, Yukawa E, and Higuchi S (2000) Chronopharmacology of antitumor effect induced by interferon-beta in tumor-bearing mice. J Pharmacol Exp Ther 2000 294:746-752.
28. Wang J, Quan N, and Heikin J (1998) Human endothelial cells are exceptionally sensitive to loss ofmethionine aminopeptidase-2. Proc Am Assoc Cancer Res 39:98.
29. Wassberg E, Pahlman S, Westlin JE, and Christofferson R (1997) The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats. Pediatr Res 41:327-333.
30. Yanase T, Tamura M, Fujita K, Kodama S, and Tanaka K (1993) Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 53:2566-2570.